Literature DB >> 17997113

Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV.

Matthaios Speletas1, Anna Kioumi, Gedeon Loules, Prodromos Hytiroglou, John Tsitouridis, John Christakis, Anastasios E Germenis.   

Abstract

Mutations in the SLC40A1 gene result in a dominant genetic disorder [ferroportin disease; hereditary hemochromatosis type (HH) IV], characterized by iron overload with two different clinical manifestations, normal transferrin saturation with macrophage iron accumulation (the most prevalent type) or high transferrin saturation with hepatocyte iron accumulation (classical hemochromatosis phenotype). In previous studies, the mutational analysis of SLC40A1 gene has been performed at the genomic DNA level by PCR amplification and direct sequencing of all coding regions and flanking intron-exon boundaries (usually in 9 PCR reactions). In this study, we analyzed the SLC40A1 gene at the mRNA level, in two RT-PCR reactions, followed by direct sequencing and/or NIRCA (non-isotopic RNase cleavage assay). This protocol turned out to be rapid, sensitive and reliable, facilitating the detection of the SLC40A1 gene mutations in two patients with hyperferritinemia, normal transferrin saturation and iron accumulation predominantly in macrophages and Kupffer cells. The first one displayed the well-described alteration V162 Delta and the second a novel mutation (R178G) that was further detected in two relatives in a pedigree analysis. The proposed procedure would facilitate the wide-range molecular analysis of the SLC40A1 gene, contributing to better understanding the pathogenesis of the ferroportin disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997113     DOI: 10.1016/j.bcmd.2007.09.011

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  8 in total

1.  Manganese efflux in Parkinsonism: insights from newly characterized SLC30A10 mutations.

Authors:  Margaret R DeWitt; Pan Chen; Michael Aschner
Journal:  Biochem Biophys Res Commun       Date:  2013-01-26       Impact factor: 3.575

Review 2.  Ethnic Differences in Iron Status.

Authors:  Wanhui Kang; Alexa Barad; Andrew G Clark; Yiqin Wang; Xu Lin; Zhenglong Gu; Kimberly O O'Brien
Journal:  Adv Nutr       Date:  2021-10-01       Impact factor: 8.701

3.  Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.

Authors:  Roman Mayr; Andreas R Janecke; Melanie Schranz; William J H Griffiths; Wolfgang Vogel; Antonello Pietrangelo; Heinz Zoller
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

4.  Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease.

Authors:  André Viveiros; Marlene Panzer; Nadja Baumgartner; Benedikt Schaefer; Armin Finkenstedt; Benjamin Henninger; Igor Theurl; Karin Nachbaur; Günter Weiss; Roland Haubner; Clemens Decristoforo; Herbert Tilg; Heinz Zoller
Journal:  Liver Int       Date:  2020-06-12       Impact factor: 5.828

5.  FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia.

Authors:  Gedeon Loules; Fani Kalala; Nikolaos Giannakoulas; Emmanouil Papadakis; Panagiota Matsouka; Matthaios Speletas
Journal:  BMC Blood Disord       Date:  2009-02-02

Review 6.  Ferroportin disease: pathogenesis, diagnosis and treatment.

Authors:  Antonello Pietrangelo
Journal:  Haematologica       Date:  2017-11-03       Impact factor: 9.941

7.  The SLC40A1 R178Q mutation is a recurrent cause of hemochromatosis and is associated with a novel pathogenic mechanism.

Authors:  Chandran Ka; Julie Guellec; Xavier Pepermans; Caroline Kannengiesser; Cécile Ged; Wim Wuyts; David Cassiman; Victor de Ledinghen; Bruno Varet; Caroline de Kerguenec; Claire Oudin; Isabelle Gourlaouen; Thibaud Lefebvre; Claude Férec; Isabelle Callebaut; Gérald Le Gac
Journal:  Haematologica       Date:  2018-07-12       Impact factor: 9.941

Review 8.  Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features.

Authors:  L Tom Vlasveld; Roel Janssen; Edouard Bardou-Jacquet; Hanka Venselaar; Houda Hamdi-Roze; Hal Drakesmith; Dorine W Swinkels
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.